In the BioHarmony Drug Report Database

"Preview" Icon

Crizanlizumab-tmca

Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.

 

Trade Name

 

Adakveo
 

Common Name

 

crizanlizumab
 

ChEMBL ID

 

CHEMBL4297734
 

Indication

 

sickle cell anemia
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Crizanlizumab-tmca structure rendering